RPL4 Antibody

What is RPL4 and why is it significant in cellular biology?

RPL4 (Ribosomal Protein L4) is a component of the 60S subunit of ribosomes and belongs to the L4E family. It functions as an essential part of the large ribosomal subunit responsible for protein synthesis in cells . Beyond its structural role in ribosomes, RPL4 has emerged as a multifunctional protein involved in several cellular processes. By interacting with transcription factors like c-Myb, RPL4 plays an important role in c-myc expression regulation, indicating its significance extends beyond ribosomal assembly .

Recent research has revealed RPL4's critical involvement in viral pathogenesis, particularly in Epstein-Barr Virus (EBV) infection. Studies show that RPL4 forms complexes with EBNA1 (EBV Nuclear Antigen 1) and Nucleolin to stabilize EBNA1 binding to the origin of plasmid replication (oriP), which is essential for EBV genome maintenance and viral gene expression .

What experimental applications are RPL4 antibodies suitable for?

RPL4 antibodies have been validated for multiple applications in molecular and cellular biology research:

These applications enable researchers to study RPL4 expression, localization, and interactions across various experimental contexts .

How do I select the appropriate RPL4 antibody for my research?

When selecting an RPL4 antibody, consider these research-critical factors:

• Target species reactivity: Confirm the antibody has been validated for your experimental species (human, mouse, etc.). For instance, antibodies like ab154907 have been validated for both human and mouse samples .

• Application compatibility: Verify the antibody is validated for your specific application. Some antibodies work well for multiple applications (WB, IHC, IF), while others may be optimized for specific techniques .

• Antibody type: Choose between:

  • Polyclonal antibodies: Offer broader epitope recognition but potentially lower specificity

  • Monoclonal antibodies: Provide consistent results with higher specificity to a single epitope

  • Recombinant antibodies: Ensure lot-to-lot consistency for reproducible results

• Immunogen information: Review the immunogen details. For example, ab154907 was generated using a recombinant fragment within human RPL4 (amino acids 50-350) , while other antibodies may target different regions.

• Validation data: Examine published validation data, including Western blot bands, immunofluorescence patterns, and cross-reactivity profiles to ensure specificity for your experimental system .

What are the optimal protocols for detecting RPL4 by Western blotting?

For optimal Western blotting of RPL4 (predicted molecular weight: 48 kDa):

• Sample preparation:

  • Prepare whole cell lysates from appropriate cell lines (validated examples include Raji, K562, and NCI-H929 cells)

  • Load 20-30 μg of total protein per lane for optimal detection

• Gel selection and transfer:

  • Use 10% SDS-PAGE gels for optimal resolution of the 48 kDa RPL4 protein

  • Transfer to PVDF or nitrocellulose membranes using standard protocols

• Antibody incubation:

  • Block membrane with 5% non-fat milk or BSA in TBST

  • Dilute primary RPL4 antibody appropriately (e.g., 1:1000 for ab154907, or 1:5000-1:50000 for other antibodies)

  • Incubate with appropriate HRP-conjugated secondary antibody (e.g., anti-rabbit IgG)

• Detection considerations:

  • Verify the expected band size (48 kDa)

  • Be aware that some degradation products may be visible

  • Include appropriate positive controls (e.g., HEK-293, HeLa, or HepG2 cell lysates)

For quantitative analyses, consider normalizing RPL4 expression to housekeeping proteins and using appropriate imaging systems for signal detection.

What are the recommended protocols for immunofluorescence staining of RPL4?

For optimal immunofluorescence detection of RPL4:

• Cell preparation:

  • Culture cells on coverslips or in chamber slides to 70-80% confluency

  • Validated cell lines include HepG2 and other human cell lines

• Fixation and permeabilization:

  • Use ice-cold methanol fixation for optimal RPL4 epitope preservation

  • Alternative fixation methods (4% paraformaldehyde) may work but require optimization

• Antibody staining:

  • Block with appropriate serum (typically 1-5% BSA or normal serum)

  • Dilute primary RPL4 antibody in blocking solution (e.g., 1:500 for ab154907 or 1:125-1:500 for other antibodies)

  • Incubate overnight at 4°C or for 1-2 hours at room temperature

  • Wash thoroughly and incubate with fluorophore-conjugated secondary antibody

• Nuclear counterstaining and mounting:

  • Counterstain nuclei with DAPI or Hoechst 33342

  • Mount with appropriate anti-fade mounting medium

• Expected pattern:

  • RPL4 typically shows cytoplasmic localization

  • Note that under certain experimental conditions (e.g., EBV infection), RPL4 can redistribute to cell nuclei

This protocol should allow for clear visualization of RPL4 subcellular localization and enable co-localization studies with other proteins of interest.

How should I optimize immunohistochemical (IHC) staining of RPL4 in tissue samples?

For optimal IHC detection of RPL4 in formalin-fixed, paraffin-embedded (FFPE) tissues:

• Tissue preparation and antigen retrieval:

  • Section FFPE tissues at 4-6 μm thickness

  • Perform heat-induced epitope retrieval using EDTA-based buffer (pH 8.0) for 15 minutes

  • This retrieval method has been validated for both human and mouse tissues

• Blocking and antibody incubation:

  • Block endogenous peroxidase activity with 3% H₂O₂

  • Block non-specific binding with appropriate serum

  • Dilute RPL4 primary antibody (e.g., 1:500 for ab154907 or 1:250-1:1000 for other antibodies)

  • Incubate overnight at 4°C or for 1-2 hours at room temperature

• Detection system:

  • Use appropriate HRP-polymer or ABC detection systems

  • Develop with DAB substrate and counterstain with hematoxylin

  • Mount with permanent mounting medium

• Controls and interpretation:

  • Include positive control tissues (e.g., human U87 xenograft tissue, mouse pancreas, or mouse colon)

  • RPL4 primarily shows cytosolic staining in normal tissues

  • Evaluate staining intensity and distribution relative to controls

This protocol has been validated for human xenograft tissues and mouse tissues including pancreas and colon, with consistent cytosolic staining patterns .

How does RPL4 contribute to Epstein-Barr Virus (EBV) genome maintenance and what techniques reveal this function?

RPL4 plays a crucial role in EBV persistence through its interaction with EBNA1 (Epstein-Barr Virus Nuclear Antigen 1) at the origin of plasmid replication (oriP). Research has revealed several mechanisms that can be studied through specific techniques:

• Protein complex formation analysis:

  • RPL4 forms a scaffold with Nucleolin (NCL) to support EBNA1 binding to oriP

  • This complex can be studied using co-immunoprecipitation assays followed by Western blotting or mass spectrometry

  • The N-terminus of RPL4 cooperates with NCL-K429 to support EBNA1 and oriP-mediated episome maintenance

• Functional analysis of RPL4 in EBV maintenance:

  • RPL4 shRNA knockdown experiments demonstrate decreased EBNA1 activation of oriP luciferase reporters

  • Reduced EBNA1 DNA binding in lymphoblastoid cell lines can be measured using ChIP assays

  • EBV genome copy number per lymphoblastoid cell decreases with RPL4 knockdown, measurable by qPCR

• Chromatin modification analysis:

  • The C-terminal K380 and K393 residues of NCL induce oriP DNA H3K4me2 modification

  • This promotes EBNA1 activation of oriP-dependent transcription

  • These modifications can be detected using ChIP assays with specific histone modification antibodies

• Nuclear redistribution of RPL4:

  • EBV infection increases RPL4 expression and redistributes it to cell nuclei

  • This can be visualized using immunofluorescence microscopy and quantified with subcellular fractionation followed by Western blotting

Understanding these mechanisms provides insights into how EBV exploits host proteins for persistent infection and reveals potential targets for therapeutic intervention in EBV-associated diseases.

What is the relationship between RPL4 and its dedicated chaperone Acl4, and how can this interaction be studied?

RPL4 requires a dedicated chaperone, Acl4, for proper transport and assembly into ribosomes. This specialized interaction can be studied through various experimental approaches:

• Mapping the interaction domains:

  • Yeast two-hybrid (Y2H) assays reveal that Acl4 binds to the long internal loop of Rpl4 (specifically amino acids 88-114)

  • In vitro binding assays using purified proteins confirm this interaction, with a slightly extended binding region (amino acids 72-114)

• Co-purification experiments:

  • Tandem-affinity purification (TAP) of N-terminally tagged Rpl4a.N264 and Rpl4a.N291 co-purifies Acl4

  • Similarly, C-terminally TAP-tagged Acl4 specifically co-purifies non-ribosome associated Rpl4

  • These experiments suggest Acl4 binds newly synthesized Rpl4 before its incorporation into ribosomes

• Functional significance analysis:

  • Deletion of the ACL4 gene (Δacl4 null mutant) results in severe growth defects

  • Polysome profile analysis of Δacl4 mutants shows deficient production of 60S ribosomal subunits

  • This indicates Acl4 is required for efficient ribosome biogenesis

• In vitro reconstitution:

  • Co-expression of C-terminally His-tagged Rpl4a variants with Acl4-Flag in E. coli

  • Purification via Ni-affinity chromatography followed by SDS-PAGE and Western blotting

  • This approach enables structure-function analysis of the chaperone-substrate interaction

Understanding this dedicated chaperone system provides insights into ribosome assembly pathways and the mechanisms preventing aggregation or inappropriate interactions of ribosomal proteins during their transport to the nucleus.

How can RPL4 antibodies be used to investigate extra-ribosomal functions in cellular signaling?

Beyond its canonical role in ribosome structure, RPL4 exhibits important extra-ribosomal functions that can be investigated using specialized applications of RPL4 antibodies:

• Protein-protein interaction studies:

  • Use RPL4 antibodies for co-immunoprecipitation to identify novel interaction partners

  • This approach revealed RPL4 interactions with c-Myb, influencing c-myc expression

  • Combine with mass spectrometry for unbiased identification of interaction networks

• Chromatin immunoprecipitation (ChIP):

  • Apply RPL4 antibodies in ChIP assays to investigate potential direct or indirect DNA binding

  • This method revealed RPL4's involvement in EBNA1 binding to oriP in EBV-infected cells

  • Follow with sequencing (ChIP-seq) to identify genome-wide binding patterns

• Spatial and temporal regulation analysis:

  • Use immunofluorescence with RPL4 antibodies to track subcellular redistribution

  • EBV infection has been shown to redistribute RPL4 to cell nuclei, suggesting regulated trafficking

  • Combine with live-cell imaging using tagged RPL4 constructs for dynamic studies

• Signaling pathway perturbation experiments:

  • Employ RPL4 antibodies for Western blotting to monitor expression changes following pathway stimulation or inhibition

  • Combine with phospho-specific antibodies to detect potential post-translational modifications

  • Correlate with functional outcomes to establish mechanistic links

• Proximity-dependent labeling:

  • Combine RPL4 antibodies with BioID or APEX2 proximity labeling approaches to identify proteins in close proximity to RPL4 in different cellular compartments

  • This can reveal context-specific protein neighborhoods and potential novel functions

These approaches leverage RPL4 antibodies to move beyond simple detection and enable mechanistic insights into RPL4's diverse cellular functions.

How can I optimize RPL4 antibody performance when faced with high background or non-specific binding?

When encountering high background or non-specific binding with RPL4 antibodies, implement these optimization strategies:

• Western blotting optimization:

  • Increase blocking stringency with 5% BSA instead of milk, or add 0.1-0.3% Tween-20

  • Optimize primary antibody concentration by testing dilutions from 1:5000 to 1:50000

  • Increase washing duration and volume between antibody incubations

  • Consider alternative membranes (PVDF vs. nitrocellulose) based on signal-to-noise ratio

  • Test different secondary antibody dilutions and manufacturers

• Immunohistochemistry refinement:

  • Optimize antigen retrieval: EDTA-based buffer at pH 8.0 has been validated for RPL4 detection

  • Extend blocking time or increase blocking reagent concentration

  • Test a range of primary antibody dilutions (1:250-1:1000)

  • Implement additional avidin/biotin blocking steps if using biotin-based detection systems

  • Pre-absorb primary antibody with tissue powder to remove non-specific binding

• Immunofluorescence improvements:

  • Optimize fixation method (ice-cold methanol has been validated for RPL4)

  • Reduce primary antibody concentration (test dilutions from 1:125-1:500)

  • Add 0.1-0.3% Triton X-100 to all solutions to reduce hydrophobic interactions

  • Include 10% normal serum from the secondary antibody host species in blocking buffer

  • Extend washing steps and include 0.05% Tween-20 in wash buffer

• Validation controls:

  • Include a known positive control (HepG2, HEK-293, or HeLa cells)

  • Implement negative controls (primary antibody omission, isotype control)

  • Consider siRNA knockdown of RPL4 to confirm specificity

  • Evaluate staining pattern consistency with known subcellular localization (typically cytoplasmic)

These systematic approaches can significantly improve signal specificity while reducing background interference.

What are the key considerations when designing experiments to differentiate between ribosomal and extra-ribosomal functions of RPL4?

Distinguishing between RPL4's canonical ribosomal role and its emerging extra-ribosomal functions requires specialized experimental designs:

• Subcellular fractionation approaches:

  • Perform rigorous separation of cytoplasmic, nuclear, and nucleolar fractions

  • Analyze RPL4 distribution across these fractions using Western blotting

  • Compare with distribution of established ribosomal markers (e.g., Rpl3, Rpl5) and non-ribosomal nuclear proteins

  • Look for RPL4 populations that segregate differently from canonical ribosomal markers

• Protein complex analysis:

  • Use size exclusion chromatography to separate ribosomal from non-ribosomal complexes

  • Follow with Western blotting or mass spectrometry to identify complex components

  • Implement sucrose gradient centrifugation to distinguish free RPL4 from ribosome-associated forms

  • Apply tandem affinity purification to isolate distinct RPL4-containing complexes

• Mutational analysis strategies:

  • Design RPL4 mutants that selectively disrupt either ribosomal incorporation or extra-ribosomal interactions

  • For example, target the binding interface with Acl4 (amino acids 72-114) or other specific domains

  • Express these mutants in cells and assess their functionality in ribosomal versus extra-ribosomal contexts

  • Monitor effects on specific pathways, such as c-myc expression or EBV genome maintenance

• Temporal separation techniques:

  • Use inducible expression systems to introduce tagged-RPL4 and track its initial interactions

  • New synthesis will first engage in extra-ribosomal interactions before incorporation into mature ribosomes

  • This approach can temporally separate pre-ribosomal from mature ribosomal functions

• Functional readouts:

  • Measure global translation (ribosomal function) using puromycin incorporation or polysome profiling

  • Simultaneously assess specific extra-ribosomal functions (e.g., EBNA1 binding to oriP, c-myc expression)

  • Look for conditions or mutations that differentially affect these distinct functional readouts

These strategies enable researchers to parse the complex multi-functionality of RPL4 and determine how its various roles are regulated and coordinated.

How can I quantitatively analyze RPL4 expression patterns across different tissue or cell types?

For rigorous quantitative analysis of RPL4 expression across different biological samples:

• Western blot quantification:

  • Use validated RPL4 antibodies at optimal dilutions (1:5000-1:50000)

  • Include loading controls appropriate for your experimental context (β-actin, GAPDH, or total protein staining)

  • Implement technical replicates (minimum triplicate) and biological replicates

  • Use standard curves with recombinant RPL4 protein for absolute quantification

  • Apply appropriate normalization methods and statistical analyses

• Immunohistochemistry scoring systems:

  • Develop a semi-quantitative scoring system based on:

    • Staining intensity (0=negative, 1=weak, 2=moderate, 3=strong)

    • Percentage of positive cells (0-100%)

  • Calculate H-scores (intensity × percentage) or quick scores

  • Implement digital pathology tools for unbiased quantification

  • Have multiple independent observers score samples to ensure reproducibility

• Fluorescence-based quantification:

  • Use immunofluorescence with RPL4 antibodies at consistent dilutions (1:125-1:500)

  • Acquire images with identical microscope settings across all samples

  • Measure mean fluorescence intensity per cell using image analysis software

  • Normalize to appropriate reference markers

  • Analyze sufficient cell numbers for statistical significance (>100 cells per condition)

• Flow cytometry analysis:

  • Prepare single-cell suspensions from tissues or cultured cells

  • Perform intracellular staining for RPL4 using validated antibodies (0.40 μg per 10^6 cells)

  • Include appropriate isotype controls

  • Measure median fluorescence intensity (MFI) across populations

  • Gate on specific cell types using appropriate markers for heterogeneous samples

• Multi-level analysis integration:

  • Correlate protein-level data with transcriptome data when available

  • Consider tissue-specific or cell-type-specific variations in reference gene expression

  • Apply appropriate statistical methods for multiple comparisons

  • Report both statistical and biological significance of observed differences

These methodologies enable robust quantitative comparisons of RPL4 expression across experimental conditions, providing insights into its regulation and potential functional significance in different contexts.

How might RPL4 be involved in cancer biology, and what experimental approaches can investigate this relationship?

Recent research suggests RPL4 may have significant roles in cancer biology, which can be investigated through several experimental approaches:

• Expression correlation studies:

  • Analyze RPL4 expression in cancer tissues versus matched normal tissues using immunohistochemistry

  • RPL4 antibodies have been validated for human stomach cancer and intrahepatic cholangiocarcinoma tissues

  • Correlate expression levels with clinical parameters and patient outcomes

  • Examine co-expression patterns with known oncogenes like c-myc

• Functional manipulation experiments:

  • Implement RPL4 knockdown or overexpression in cancer cell lines

  • Assess effects on:

    • Cell proliferation rates

    • Migration and invasion capabilities

    • Resistance to apoptosis

    • Response to chemotherapeutic agents

  • Use validated cell lines like HeLa, HepG2, and K-562 for consistency with antibody validation data

• Signaling pathway analysis:

  • Investigate RPL4's influence on cancer-relevant pathways through:

    • Western blotting for key signaling molecules after RPL4 manipulation

    • Protein-protein interaction studies using co-immunoprecipitation with RPL4 antibodies

    • Reporter assays for transcriptional activity of cancer-relevant genes

  • Focus on previously identified connections such as c-Myb interactions and c-myc expression regulation

• Cancer-specific RPL4 complex characterization:

  • Perform tandem affinity purification of RPL4 from cancer versus normal cells

  • Identify differential protein interactions by mass spectrometry

  • Validate findings using co-immunoprecipitation with RPL4 antibodies

  • Assess functional relevance through targeted disruption of specific interactions

• In vivo tumor models:

  • Establish xenograft models with RPL4-manipulated cancer cells

  • Analyze tumor growth, invasion, and metastasis

  • Perform immunohistochemistry using validated RPL4 antibodies (1:250-1:1000 dilution)

  • Correlate RPL4 expression patterns with tumor behavior and response to therapy

These approaches can reveal how RPL4's ribosomal and extra-ribosomal functions may contribute to cancer development, progression, and therapeutic resistance.

What are the methodological approaches for studying post-translational modifications of RPL4 and their functional significance?

Investigating post-translational modifications (PTMs) of RPL4 requires specialized methodologies:

• Mass spectrometry-based PTM identification:

  • Immunoprecipitate RPL4 using validated antibodies

  • Perform tryptic digestion followed by LC-MS/MS analysis

  • Implement enrichment strategies for specific modifications:

    • Phosphopeptide enrichment (TiO₂, IMAC)

    • Ubiquitin remnant motif antibodies

    • Acetyl-lysine antibodies

  • Use database searching with PTM variable modifications

  • Validate findings with targeted MS approaches (PRM, MRM)

• Site-specific antibody development and validation:

  • Generate antibodies against specific modified RPL4 peptides

  • Validate specificity using peptide competition assays

  • Confirm recognition of endogenous modified RPL4

  • Apply in Western blotting, immunofluorescence, and immunoprecipitation

  • Use to track modification dynamics under different conditions

• Functional analysis of PTM sites:

  • Generate site-specific mutants (phosphomimetic, phosphodeficient, etc.)

  • Express in appropriate cellular contexts after endogenous RPL4 depletion

  • Assess effects on:

    • Ribosome incorporation

    • Interaction with binding partners (Acl4, EBNA1, etc.)

    • Subcellular localization

    • Stability and half-life

• PTM crosstalk investigation:

  • Examine interdependencies between different modifications

  • Study modification dynamics during cell cycle, stress, or differentiation

  • Use inhibitors of specific PTM enzymes to disrupt modification patterns

  • Apply proximity labeling techniques to identify PTM enzymes in RPL4's vicinity

• Context-dependent modification analysis:

  • Compare RPL4 modifications between:

    • Free versus ribosome-incorporated RPL4

    • Normal versus EBV-infected cells

    • Different cancer cell types

  • Correlate with functional readouts such as protein synthesis rates, c-myc expression, or EBNA1 binding

These approaches enable comprehensive characterization of RPL4's modification landscape and provide insights into how PTMs regulate its diverse functions.

What are the emerging technological advances that might enhance RPL4 antibody applications in research?

Several technological advances promise to expand and enhance RPL4 antibody applications:

• Single-cell protein analysis technologies:

  • Integration of RPL4 antibodies with single-cell Western blotting platforms

  • Mass cytometry (CyTOF) applications using metal-conjugated RPL4 antibodies

  • Single-cell proteomics with antibody-based enrichment strategies

  • These approaches will reveal cell-to-cell heterogeneity in RPL4 expression and modification

• High-resolution imaging advances:

  • Super-resolution microscopy with RPL4 antibodies for nanoscale localization

  • Expansion microscopy to physically enlarge specimens for enhanced resolution

  • Correlative light and electron microscopy (CLEM) to connect RPL4 localization with ultrastructural features

  • These methods will provide unprecedented insights into RPL4's spatial organization

• Proximity-dependent labeling technologies:

  • APEX2, BioID, or TurboID fusion systems combined with RPL4 antibodies

  • Split proximity labeling approaches to identify context-specific interactions

  • Temporal control systems to capture dynamic interaction changes

  • These techniques will map RPL4's protein neighborhood in different cellular contexts

• Antibody engineering advancements:

  • Nanobodies or single-domain antibodies against RPL4 for improved tissue penetration

  • Bispecific antibodies to simultaneously target RPL4 and interaction partners

  • Conditionally active antibody fragments that function only in specific cellular compartments

  • These tools will enhance specificity and enable novel functional studies

• Integration with spatial transcriptomics:

  • Combined protein-RNA detection using RPL4 antibodies with RNA FISH

  • Spatial proteomics with region-specific RPL4 analysis

  • Integrated multi-omics approaches correlating RPL4 protein distribution with transcriptome and epigenome

  • These integrative methods will contextualize RPL4 function within the broader cellular machinery

These technological advances will enable researchers to address increasingly sophisticated questions about RPL4 biology, from its canonical ribosomal functions to emerging roles in viral pathogenesis, cancer biology, and cellular signaling .

What are the most promising research directions for understanding RPL4's roles in disease pathogenesis beyond EBV infection?

Several promising research directions are emerging for understanding RPL4's involvement in disease:

• Cancer biology exploration:

  • Investigate RPL4's potential role in ribosome specialization driving cancer-specific translation

  • Explore connections between RPL4, c-myc regulation, and cancer progression

  • Study RPL4's interaction network alterations in different cancer subtypes

  • Evaluate RPL4 as a potential biomarker, particularly in stomach cancer and intrahepatic cholangiocarcinoma where antibodies have been validated

• Ribosomopathies and development:

  • Examine RPL4 mutations or expression changes in congenital disorders

  • Study RPL4's role in tissue-specific translation during development

  • Investigate the relationship between RPL4 and other ribosomopathy-associated proteins

  • Utilize RPL4 antibodies in developmental tissue arrays to map expression patterns

• Neurodegenerative disease connections:

  • Explore RPL4's potential roles in regulating local translation in neurons

  • Investigate RPL4 modifications or alterations in neurodegenerative disease models

  • Study potential interactions between RPL4 and neurodegenerative disease-associated proteins

  • Apply RPL4 antibodies in brain tissue sections from disease models

• Stress response and cellular adaptation:

  • Characterize RPL4's involvement in integrated stress response pathways

  • Investigate potential extraribosomal functions during cellular stress

  • Study RPL4 modification patterns under various stress conditions

  • Use RPL4 antibodies to track relocalization during stress responses

• Infection and immunity beyond EBV:

  • Expand research to other viral systems that may co-opt RPL4

  • Investigate RPL4's potential roles in ribosome specialized translation during immune responses

  • Study interactions between RPL4 and immune signaling pathways

  • Apply similar methodologies that revealed RPL4's role in EBV biology to other pathogens

These research directions will benefit from the diverse applications of RPL4 antibodies in Western blotting, immunohistochemistry, immunofluorescence, and immunoprecipitation, enabling comprehensive investigation of RPL4's multifaceted roles in health and disease .